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Neurobiology SelectMost organisms that can sense pain try to avoid it. This instinct is beneficial to survival as experiencing pain
prevents organisms from either incurring or exacerbating serious injuries. Recent studies discuss some of the
molecular components that underlie both our ability to sense pain and diseases that occur when this sensation
goes awry. Understanding the molecular basis of pain should promote the development of new analgesics.
Mechanosensation SLPs up
Sensory neurons in animal skin detect stimuli and transmit the stimuli to the
spinal cord. In worms, a stomatin-domain-containing protein, MEC-2, is re-
quired for touch sensation and is thought to be part of a protein complex that
makes up the ENaC Na+ channel. Wetzel et al. (2006) identify a homolog of
mec-2, stomatin-like protein 3 (SLP3), expressed in sensory neurons and
show that this protein is essential for triggering the response to mechanical
stimuli. These investigators recorded the conduction velocity and physiolog-
ical properties of single sensory neurons in an in vitro skin nerve preparation
where the skin is removed with the saphenous nerve (major branch of the
femoral nerve) still attached. This assay is routinely used to measure mech-
anoreception. In mice carrying mutations in SLP3, 30%–40% of the myelin-
ated mechanoreceptors displayed no mechanosensitivity. They examined
whether SLP3 was required for mechanosensitive currents as is the case
with its worm counterpart MEC-2. Thirty-six percent of sensory neurons
from SLP3 mutant mice had no response to mechanical stimulation. Wetzel
et al. (2006) showed that SLP3 interacts with components of acid-sensitive
ion channels that have been implicated in mechanoreceptor sensitivity. Their
results indicate that SLP3 mutant mice have reduced ability to discriminate
between different surfaces and exhibit reduced perception of touch. After nerve injury, a small amount of stimulation
(brushing the skin, for example) can cause severe pain. The authors injured the sciatic nerve of wild-type and SLP3
mutant mice. The wild-type mice were sensitive to low levels of stimulation, whereas the SLP3 mutant mice were not.
These results suggest that targeting a mechanotransduction molecule like SLP3 may alleviate certain types of
chronic pain in human patients.
C. Wetzel et al. (2006). Nature. Published online December 13, 2006. 10.1038/nature05394.
SCN9A Maintains a Painful Balance
Two recent studies place the product of the SCN9A gene at the heart of pain pathways in humans. Cox et al. (2006)
analyzed from three families in Northern Pakistan six individuals who do not feel pain of any sort. These individuals
can sense other stimuli, such as touch and temperature, and seem to be impaired only in their ability to experience
pain. Using a positional cloning strategy, Cox et al. (2006) identified several nonsense mutations in the SCN9A gene
in these individuals. Members of the first family had a single nucleotide mutation in this gene, those from the second
family had a single base deletion, and those from the third family had a single base substitution. This gene encodes
Nav1.7, a subunit of a voltage-gated sodium channel, which is highly expressed in peripheral sensory neurons
and sympathetic neurons. These neurons transmit pain signals to the dorsal root ganglion and the spinal cord.
The authors performed patch-clamping experiments on cultured cells expressing wild-type or mutant versions (cor-
responding to the mutations in patients) of Nav1.7 as well as two other essential components of voltage-gated Na
+
channels. Channels in cells expressing the mutant constructs were nonfunctional. The authors conclude that the
inability of members of these three families to feel pain may be due to the fact that their peripheral neurons that
normally sense pain cannot generate action potentials due to aberrant function of Nav1.7 voltage-gated sodium
ion channels.
Interestingly, Fertleman et al. (2006) discovered that SCN9A is the gene mutated in the Paroxysmal extreme pain
disorder (PEPD; also known as familial rectal pain), an inherited disease that causes intense burning pain in the
rectum, the eyes, and the lower jaw and flushing around those areas. Eight out of thirteen families had missense
mutations in SCN9A. Seven out of the eight mutations affect amino acids that are conserved in other voltage-gated
Na+ channel a subunits. Their location predicts that these mutations would affect the inactivation of the channel. The
properties of these channels were examined in cultured cells expressing wild-type Nav1.7 ion channels and three
mutant versions based on the mutations found in patients. All three mutations impaired channel inactivation indicat-
ing that the continuous firing of the peripheral neurons that sense pain is one of the features that underlies this
disease. Interestingly, this channel is also mutated in another pain disorder, primary erythermalgia, in which the
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activation threshold of the Nav1.7 channel is increased. Both of these studies indicate that Nav1.7 voltage-gated
sodium ion channels, which are expressed only in a subset of neurons, would be excellent targets for designing
new analgesic drugs.
J.J. Cox et al. (2006). Nature 444, 894–898.
C.R. Fertleman et al. (2006). Neuron 52, 767–774.
The Painful Side of Dynorphin A
Dynorphin A is a natural opioid peptide produced by animals including humans. By activating opioid receptors, opi-
oid peptides may act as natural analgesics especially against chronic pain. Studies of chronic pain have shown
elevated amounts of dynorphin A in the spinal cord. Curiously, this pool of dynorphin A appears to contribute to
rather than alleviate chronic pain. This result prompted Lai et al. (2006) to investigate how dynorphin A mediates
this effect. Using a fragment of dynorphin A that binds poorly to opioid receptors, the authors show that this fragment
causes an increase in the intracellular Ca2+ concentration in a hybridoma cell line (F-11). This effect is not observed
when Ca2+ influx is disrupted and when voltage-sensitive Ca2+ channels are inhibited. The authors then showed that
dynorphin A activates Ca2+ influx in F-11 cells and an antagonist to the bradykinin B2 receptor blocked this effect.
Both the smaller fragment of dynorphin A and the full-length peptide bind to the bradykinin receptors, B1 and B2. The
authors also showed that the cellular signaling pathways activated in response to dynorphin A binding to B2 are
different from those activated when dynorphin A binds to opioid receptors. Injection of the dynorphin A fragment
into the lumbar region of rats elicits a pain response within 30 min (the rats exhibit hypersensitivity to touch in the
hind paw). The authors show that mice lacking the B2 receptor displayed normal hypersensitivity when injected
with the dynorphin A fragment. Moreover, bradykinin antagonists (HOE140) reversed neuropathic pain maintained
by endogenous dynorphin A. These results may cause the re-evaluation of the role of endogenous opioids in the
relief against chronic pain and may promote the development of therapies to prevent their ability to promote pain.
J. Lai et al. (2006). Nat. Neurosci. 9, 1534–1540. Published online November 19, 2006. 10.1038/nn1804.
A Tiny Helper to Ease the Pain
Irritable bowel syndrome is a common gastrointestinal disease character-
ized by severe abdominal pain, bloating, and altered bowel movements.
Rousseaux et al. (2006) set out to uncover how probiotics (dietary supple-
ments containing potentially beneficial bacteria or yeast) could alleviate
the symptoms of this disease. These investigators examined whether probi-
otics upregulated factors such as opioid receptors that would help to relieve
the painful symptoms of the disease. They tested five bacterial strains and
found that the Lactobacillus acidophilus strain NCFM induces increased
expression of m-opioid receptors, cannabinoid receptors, and the NF-kB
signaling pathway in cultured human epithelial cells. They then orally fed
NCFM to rats with chronic colonic hypersensitivity, which is similar to irrita-
ble bowel syndrome. Treated rats appeared to bear the visceral pain better
than control rats that were not fed NCFM and to the same degree as rats that
were administered a standard dose of morphine. Furthermore, NCFM en-
hanced (by 65%) the analgesic effect provided by low doses of morphine.
Thus probiotics could be a safe, cheap, and nonaddictive way to counter
the miserable symptoms of irritable bowel syndrome.
C. Rosseaux et al. (2006). Nat. Med. Published online December 10, 2006.
10.1038/nm1521.
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Intestinal epithelial cells (DNA in blue)
stimulated for 3 hr by the Lactobacillus
acidophilus strain NCFM show increased
expression of the m-opioid receptor (red).
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